EyePoint Pharmaceuticals (EYPT) Stock: Buy, Sell, or Hold?
EYPT - EyePoint Pharmaceuticals, Inc. Common Stock
$4.23
-0.02 (-0.47%)
âŧ
5d:
-7.34%
30d:
-68.74%
90d:
-66.16%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 8, 2026 at $4.63 · last confirmed Sep 9, 2026
Strength: 7.2/10
Get Alerted When EYPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EYPT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EYPT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: EYPT is currently trading at $4.23, which is considered slightly low relative to its 30-day fair value range of $3.70 to $11.66.
Technical Outlook: Technically, EYPT is in a strong downtrend. Immediate support is located at $4.10, while resistance sits at $4.92.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.91 (+512.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EYPT is in a strong downtrend. Immediate support is located at $4.10, while resistance sits at $4.92.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $25.91 (+512.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.70 -
$11.66
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 512.5% below Wall St target ($25.91)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.70 -
$11.66
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.10
Resistance Level
$4.92
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.53
Wall Street Target
$25.91
(+512.5%)
Revenue Growth (YoY)
161.7%
Share & Embed Analysis
Last updated: September 12, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EYPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Ramiro Ribeiro
SELL
2437 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
